PlasmaGen Biosciences Secures Rs 150 Crore to Expand Plasma-Derived Therapies

PlasmaGen Biosciences, backed by Eight Road Ventures, raised Rs 150 crore led by ViNS Bioproducts. Funds will scale international operations, expand its product portfolio, and enhance manufacturing. The company focuses on plasma-derived therapies, aiming to address India’s critical medicine supply gap. Commercial operations began in 2024 at its Kolar facility.